Similarly, HMGB2 knockdown impairs GBM cell viability and invasiveness in vitro, reduces tumor volume in vivo, and enhances sensitivity to temozolomide, positioning it as a viable target for combinatorial therapy (39). The gene discussed is HMGB2; the disease is neoplasm.